<DOC>
	<DOC>NCT02742623</DOC>
	<brief_summary>This study aims to collect patient reported outcomes and assess treatment satisfaction in active cancer patients treated with rivaroxaban for VTE (venous thromboembolism).</brief_summary>
	<brief_title>A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult female and male patients with active cancer other than fully treated basalcell or squamouscell carcinoma of the skin (active cancer defined as the diagnosis or treatment of cancer in the previous &lt; 6 months or recurrent or metastatic cancer) Patients that have been treated with standard of care anticoagulation (Low Molecular Weight Heparin / Vitamin K Antagonist) for treatment of DVT and/ or PE (index VTE event) and/ or prevention of recurrent DVT and PE for at least 4 weeks prior to inclusion in the study Patients for whom the decision was made to start rivaroxaban for treatment of DVT and/ or PE and/ or prevention of recurrent DVT and PE Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 Patients who are willing to participate in this study (signed informed consent) Patients who are available for followup with a life expectancy &gt;6 months The contraindications according to the local marketing authorization must be considered Patients who developed an index VTE event despite chronic anticoagulant therapy Patients receiving apixaban, edoxaban or dabigatran or any investigational drug as the initial therapy for the index VTE event Patients participating in an investigational program with interventions outside of routine clinical practice with exception of oncology investigational trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Deep Venous Thrombosis</keyword>
	<keyword>Pulmonary Embolism</keyword>
</DOC>